RTR888

AssetAlso iMG

iPSC-derived microglial progenitors to renew the brain's immune cells

Stage: Preclinical
Modality: Cell therapy
Target: Not known; 0
Indications: 0
Trials: 1
Developer

Indications

1

No named disease
Preclinical, retro.bio, 8 Oct 2026

In the full profile

Owner and partners1
Signals1

Every asset’s record: target, stage, trials and the evidence behind it.